High-dose chemotherapy and PBPC autografting in indolent lymphomas: Evaluation of minimal residual disease and molecular follow-up.

被引：0
|
作者：
Corradini, P
Astolfi, M
Caracciolo, D
Bondesan, P
Voena, C
Vitolo, U
Cinque, F
Pileri, A
Tarella, C
机构：
[1] Az Osped S Giovanni Battista, Div Osped Ematol, Torino, Italy
[2] Univ Turin, Az Osped S Giovanni Battista, Div Ematol, Torino, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
634
引用
收藏
页码：S183 / S183
页数：1
相关论文
共 50 条
  • [41] Nonmyeloablative conditioning followed by allogeneic transplantation has a better outcome than high-dose chemotherapy plus autografting in non Hodgkin lymphomas with T-cell histology.
    Corradini, P
    Dodero, A
    Zallio, F
    Caracciolo, D
    Ciceri, F
    Cuttica, A
    Gianni, AM
    Pileri, A
    Tarella, C
    BLOOD, 2002, 100 (11) : 427A - 427A
  • [42] Qualitative and quantitative molecular follow up of minimal residual disease after non myeloablative allografting for multiple myeloma.
    Bruno, B
    Ladetto, M
    Astolfi, M
    Veneziano, L
    Cimolin, L
    Galletto, E
    Pagliano, G
    Rotta, M
    Mordini, N
    Giaccone, L
    Omedè, P
    Battaglio, S
    Storb, R
    Boccadoro, M
    BLOOD, 2004, 104 (11) : 366B - 366B
  • [43] High-dose chemotherapy (HDC) in high-risk primary breast cancer (PBC): A long follow-up of monoinstitutional experience
    Aieta, M.
    D'Addetta, C.
    Latiano, T. P.
    Capotorto, A. M.
    Piano, A.
    Maiello, E.
    ANNALS OF ONCOLOGY, 2006, 17 : VII142 - VII142
  • [44] Erratum: Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
    A Venditti
    L Maurillo
    F Buccisano
    G Del Poeta
    C Mazzone
    A Tamburini
    M I Del Principe
    M I Consalvo
    P De Fabritiis
    L Cudillo
    A Picardi
    A Franchi
    F L Coco
    S Amadori
    Leukemia, 2004, 18 : 373 - 373
  • [45] Minimal residual disease in follow-up samples of patients with low grade non Hodgkin's lymphoma undergoing high-dose therapy with peripheral blood progenitor cell support: Is there an impact on the clinical outcome?
    Moos, M
    Schulz, R
    Murea, S
    Haas, R
    BLOOD, 1996, 88 (10) : 881 - 881
  • [46] LONG-TERM FOLLOW-UP RESULTS OF REDUCED DOSE CRANIOSPINAL RADIOTHERAPY AND TANDEM HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK MEDULLOBLASTOMA
    Lee, Ji Won
    Lim, Do Hoon
    Son, Meong Hi
    Sung, Ki Woong
    Cho, Hee Won
    Ju, Hee Young
    Hyun, Ju Kyung
    Yoo, Keon Hee
    Jung, Hye Lim
    Koo, Hong Hoe
    Suh, Yeon-Lim
    Joung, Yoo Sook
    Shin, Hyung Jin
    NEURO-ONCOLOGY, 2020, 22 : 394 - 394
  • [47] Qualitative IgH gene PCR to monitor residual disease in multiple myeloma patients undergoing high-dose chemotherapy.
    Martinez-Lopez, J
    Bautista, JM
    Bornstein, R
    Perez-Benavente, S
    Albizua, E
    Montejano, L
    Santorum, R
    Salama, P
    De la Serna, J
    Lahuerta, JJ
    BLOOD, 1999, 94 (10) : 177B - 177B
  • [48] Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT): 2 year follow-up.
    Nash, RA
    Bowen, JD
    McSweeney, PA
    Sullivan, KM
    Pavletic, ZS
    Maravilla, KR
    Al-Omaishi, J
    Corboy, JR
    Derrington, D
    DiPersio, J
    Georges, GE
    Gooley, T
    Holmberg, LA
    LeMaistre, CF
    Openshaw, H
    Ryan, K
    Sunderhaus, J
    Storek, J
    Zunt, J
    Storb, R
    Kraft, GH
    BLOOD, 2002, 100 (11) : 864A - 864A
  • [49] Molecular level of minimal residual disease in bone marrow before high-dose therapy and autologous stem cell transplantation is a prognostic parameter in patients with multiple myeloma
    Fenk, Roland
    Korthals, Mark
    Schnke, Nina
    Bruns, Ingmar
    Czibere, Akos
    Zohren, Fabian
    Safaian, Nancy
    Dienst, Ariane
    Ruf, Leilani
    Neumann, Frank
    Haas, Rainer
    Kronenwett, Ralf
    Kobbe, Guido
    BLOOD, 2007, 110 (11) : 448A - 448A
  • [50] High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
    Abrey, LE
    Childs, BH
    Paleologos, N
    Kaminer, L
    Rosenfeld, S
    Salzman, D
    Finlay, JL
    Gardner, S
    Peterson, K
    Hu, W
    Swinnen, L
    Bayer, R
    Forsyth, P
    Stewart, D
    Smith, AM
    Macdonald, DR
    Weaver, S
    Ramsay, DA
    Nimer, SD
    DeAngelis, LM
    Cairncross, JG
    NEURO-ONCOLOGY, 2006, 8 (02) : 183 - 188
12345